该项目拟建设以国内市场为核心基础、同步辐射全球市场的细胞与基因治疗(CGT)市场化公共服务平 台，以"赋能CGT市场化、标准化发展"为核心定位，聚焦"质粒-病毒载体-细胞药物"全产业链布局，打 造符合GMP标准的生产与检测体系，打破行业瓶颈，降低产业门槛，加速技术转化，构建可持续发展 的商业生态，打造全国最具创新示范效应的CGT公共服务平台。 该项目的建设实施，是公司立足现有核心优势，从血液制品领域向生物医药前沿赛道延伸拓展的重要战 略举措，有利于公司进一步完善生物医药领域战略布局，培育新的业务增长点，增强公司差异化竞争优 势，是公司实现战略升级、推动高质量发展的重要抓手。 卫光生物（002880）(002880.SZ)发布公告，公司拟与深圳市深业生物医药产业发展有限公司(简称深业 生物)、深圳细胞谷生物医药有限公司(简称深圳细胞谷)及深圳赛桥生物创新技术有限公司(简称赛桥生 物)共同出资设立深圳市羲和生命科技有限责任公司(暂定名，以工商部门最终登记结果为准。简称羲和 生命科技或项目公司)，建设深圳市细胞与基因治疗市场化公共服务平台。羲和生命科技初始注册资本 为1亿元，公司认缴4000万元，占羲和生命科技股权 ...

该项目的建设实施，是公司立足现有核心优势，从血液制品领域向生物医药前沿赛道延伸拓展的重要战 略举措，有利于公司进一步完善生物医药领域战略布局，培育新的业务增长点，增强公司差异化竞争优 势，是公司实现战略升级、推动高质量发展的重要抓手。 该项目拟建设以国内市场为核心基础、同步辐射全球市场的细胞与基因治疗(CGT)市场化公共服务平 台，以"赋能CGT市场化、标准化发展"为核心定位，聚焦"质粒-病毒载体-细胞药物"全产业链布局，打 造符合GMP标准的生产与检测体系，打破行业瓶颈，降低产业门槛，加速技术转化，构建可持续发展 的商业生态，打造全国最具创新示范效应的CGT公共服务平台。 智通财经APP讯，卫光生物(002880.SZ)发布公告，公司拟与深圳市深业生物医药产业发展有限公司(简 称深业生物)、深圳细胞谷生物医药有限公司(简称深圳细胞谷)及深圳赛桥生物创新技术有限公司(简称 赛桥生物)共同出资设立深圳市羲和生命科技有限责任公司(暂定名，以工商部门最终登记结果为准。简 称羲和生命科技或项目公司)，建设深圳市细胞与基因治疗市场化公共服务平台。羲和生命科技初始注 册资本为1亿元，公司认缴4000万元，占羲和生命科技股 ...

卫光生物2月4日公告，公司拟与深圳市深业生物医药产业发展有限公司、深圳细胞谷生物医药有限公司 及深圳赛桥生物创新技术有限公司共同出资设立深圳市羲和生命科技有限责任公司（暂定名，以工商部 门最终登记结果为准。以下简称羲和生命科技或项目公司），建设深圳市细胞与基因治疗市场化公共服 务平台。羲和生命科技初始注册资本为1亿元人民币，公司认缴4,000万元，占羲和生命科技股权比例为 40%。 ...

Core Insights - The global biopharmaceutical industry is still experiencing a "capital winter" in 2025, undergoing deep structural adjustments and facing a critical period of transformation and reconfiguration [1] - Shanghai's biopharmaceutical industry has shown resilience and steady growth, with manufacturing output reaching 209.9 billion yuan, driven by a shift towards innovative and high-quality enterprises [2] Structural Optimization: Full-Chain Innovation Development - The shift from generic drugs to innovative drugs is exemplified by the success of Silver诺药业, which launched the first original human long-acting GLP-1 drug in China, benefiting many patients with type 2 diabetes [3] -艾力斯医药's revenue surged from 530 million yuan in 2021 to 3.56 billion yuan in 2024, with a compound annual growth rate of 88.6% [3] - In 2025, Shanghai approved nine domestic Class 1 innovative drugs, ranking second nationally, and accounted for 33% of business development transactions in the country, leading the nation [3] Policy Support and Innovation Ecosystem - Over the past five years, Shanghai has approved 32 domestic Class 1 innovative drugs, maintaining its position as a leader in the industry [4] - The city has implemented forward-looking policies, such as the drug listing license holder system, to address the challenges of "having technology but no factory" [4] New Growth Areas: Diverse Expansion - Shanghai is emerging as a leader in brain-computer interface technology, with nearly 30 registered companies and significant funding in this sector [5] - The city also leads in cell and gene therapy, with 57% of the country's products launched between 2021 and September 2025 [5] AI-Driven Pharmaceutical Innovation - AI-driven drug development is reshaping research paradigms, with 英矽智能 discovering 27 preclinical candidates, 13 of which have received clinical trial approvals [6] - By the end of 2025, 英矽智能 is expected to become the first AI pharmaceutical company listed on the Hong Kong Stock Exchange, raising a record 2.277 billion HKD [6] Global Value Co-Creation - Shanghai's innovative drugs are increasingly entering global markets, transitioning from a one-time sale model to a co-creation model, enhancing their bargaining power [8] - 和铂医药's licensing transactions exceeded 7 billion USD in 2025, reflecting the growing international recognition of Shanghai's innovative drug development capabilities [8] Globalization of Innovative Medical Devices - 联影医疗 has launched over 140 proprietary products, entering more than 90 countries and regions, showcasing the global reach of Shanghai's innovative medical devices [9] - The city has established supportive policies for innovative drugs and devices that achieve registration and sales in multiple countries, providing up to 10 million yuan in support for qualifying projects [9]

Core Viewpoint - In 2025, despite increasing uncertainties in external demand, China's major provinces have stabilized their economic foundations, with several economic powerhouses achieving record GDP growth [1][3]. Economic Performance - In 2025, three provinces surpassed a GDP of 10 trillion yuan, with Guangdong leading at 14.58 trillion yuan, followed by Jiangsu at 14 trillion yuan, and Shandong breaking the 10 trillion yuan mark for the first time [3][6]. - Guangdong's GDP reached 145,846.76 billion yuan, marking its 37th consecutive year at the top of the national GDP rankings, with advanced manufacturing and high-tech manufacturing growing by 5.1% and 6.2% respectively [6]. - Jiangsu's GDP was 142,351.5 billion yuan, a 5.3% increase year-on-year, while Shandong's GDP reached 103,197 billion yuan, growing by 5.5% [6][7]. Industrial Development - The industrial sector remains a core support for Jiangsu's growth, with notable performance in high-end manufacturing, particularly in electronics and transportation equipment [6][7]. - Shandong's equipment manufacturing sector saw an 11.4% increase in value added, with significant growth in automotive and rail transport industries [7]. - In 2025, 20 provinces achieved GDP growth rates above the national average of 5%, with western provinces like Tibet leading at 7% [8]. Trade Resilience - Despite uncertainties, foreign trade showed resilience, with new energy vehicles, lithium batteries, and photovoltaic products becoming significant contributors to exports [8]. - Anhui's foreign trade exceeded 1 trillion yuan for the first time, with a 1.1 times increase in exports of the "new three items" [8]. Regional Strategies - Various provinces emphasized tailored industrial planning during their local meetings, focusing on upgrading existing industries rather than simply moving away from traditional sectors [10]. - Guangdong aims to build a competitive modern industrial system, emphasizing high-quality manufacturing and integrating artificial intelligence into its industrial framework [10][11]. - Zhejiang's strategy includes embedding AI into industrial upgrades, leveraging its strong digital economy and private sector participation [12]. Traditional Industry Enhancement - Provinces like Hubei and Henan are focusing on enhancing their traditional industries while also promoting new sectors [14][15]. - Hubei's plan includes upgrading traditional sectors like automotive and steel while fostering emerging industries such as integrated circuits and artificial intelligence [14][15]. - The strategy of "three lines advancing" aims to strengthen the competitiveness of traditional industries while supporting new and future industries [15][16].

Core Viewpoint - He Yuan Biotechnology (Shanghai) Co., Ltd. forecasts a net loss of between 237 million yuan and 195 million yuan for 2025, representing a reduction in losses by 84.81 million yuan to 127 million yuan compared to the previous year [1] Group 1: Company Performance - The company has been deeply engaged in the cell and gene therapy (CGT) field for over a decade, developing core technology clusters for vector development, production processes, and quality control [1] - As of the end of 2025, He Yuan has assisted clients in obtaining over 60 clinical trial approvals, with 14 approvals granted by the U.S. Food and Drug Administration [1] - The company has established a million-level cell bank with one-click access and full visual management, along with 14 fully automated production lines in the regenerative medicine sector [1] Group 2: Technological Advancements - Continuous investment in technology has created a differentiated competitive barrier for the company [2] - In 2025, He Yuan's viral vector upgrades, including the VPack packaging system and AAV-PANX products, are expected to achieve high production [2] - The company has introduced proprietary technologies in gene editing and nucleic acid delivery, including the micro-light gene Cas12 protein and LNP-mRNA delivery system licensing [2] Group 3: Industry Position - Analysts indicate that He Yuan, with its comprehensive service capabilities and scalable delivery systems, has secured a favorable position in the CGT industrialization process [2] - The company's ongoing investments in technology, production capacity, and ecosystem collaboration are expected to further solidify its industry-leading position and contribute to the long-term development of the cell and gene therapy sector [2]

Core Insights - Guangdong has developed 8 trillion-level and 17 hundred-billion-level modern agricultural industry clusters, leading the nation in total aquatic product output, marine fish farming output, and marine fish seedling output [1] - During the 14th Five-Year Plan period, Guangdong is advancing the construction of a modern industrial system, achieving breakthroughs in traditional, emerging, and future industries [1] - Major industrial projects such as BASF's core facility, ExxonMobil's first phase, and China Resources Microelectronics' 12-inch production line have been completed, with industries like electronic information, new energy vehicles, and low-altitude economy flourishing [1] Industry Development - Guangdong aims to elevate traditional industries such as electronics, machinery, chemicals, light industry, building materials, textiles, metallurgy, mining, and shipbuilding to mid-to-high-end levels, while strengthening brands in home appliances, food, clothing, furniture, jewelry, toys, and footwear [2] - The province will promote innovation infrastructure, technology R&D, and product upgrades, focusing on emerging industries like new energy, new materials, smart connected vehicles, robotics, pharmaceuticals, aerospace, integrated circuits, low-altitude economy, and biomanufacturing [2] - Guangdong will establish a long-term mechanism for rapid identification and precise policy implementation for new industry tracks, supported by a multi-level, systematic pilot service network and venture capital funds [2]

Core Insights - The event "CGT Drug Development Full Chain" held in Chengdu aims to gather various stakeholders to discuss the innovation pathways in the cell and gene therapy (CGT) industry, contributing to the establishment of Chengdu as a significant biopharmaceutical hub in China [1][2] Group 1: Industry Context - The cell and gene therapy sector is experiencing dual opportunities from technological breakthroughs and policy support, as highlighted in China's "14th Five-Year Plan" for biopharmaceutical development [2] - The salon focuses on key issues across the entire CGT chain, providing a platform for local industry exchange and contributing to the high-quality development of the national CGT industry [2] Group 2: Expert Insights - Experts from various fields shared insights on regulatory review, clinical trial efficiency, commercialization management, international market access strategies, and innovative payment models, identifying pain points and challenges in the industry [3] - The consensus among experts is that achieving synergy across the entire chain from research and development to payment is crucial for the sustainable development of the CGT industry [3] Group 3: Collaborative Efforts - The event facilitated in-depth discussions among industry representatives, researchers, and experts on topics such as CGT technology iteration, clinical translation challenges, cost control, and payment model innovation, reflecting the active collaboration within Chengdu's CGT ecosystem [3] - The salon's comprehensive agenda covering "research-clinical-operation-export-payment" established a multi-perspective dialogue platform, enhancing ecological collaboration and resource integration in Chengdu's CGT industry [3]

Core Insights - A Chinese research team has successfully treated patients with refractory autoimmune hemolytic anemia (AIHA) using self-developed CD19 CAR T cells, providing a new therapeutic option for patients who have failed conventional treatments [1][2] Group 1: Treatment Breakthrough - The research team established a new cell immunotherapy system specifically for patients with refractory or relapsed AIHA, achieving significant efficacy and safety, with patients experiencing long-term remission without medication [2] - For patients who relapsed after CAR T treatment, the team utilized BCMA×CD3 bispecific antibodies for targeted secondary rescue therapy, which also yielded successful outcomes [2] Group 2: Mechanism and Future Implications - The research provided a clear immunological explanation for disease relapse after CAR T cell therapy, advancing cell immunotherapy from empirical exploration to mechanism-guided precision intervention [2] - The findings suggest that relapse is not the endpoint of treatment failure, and targeted cell immunotherapy strategies can be implemented based on defined immunological mechanisms, paving the way for a sustainable model of sequential cell immunotherapy [2] Group 3: Research Support and Contributors - The study was led by Dr. Shi Jun and researcher Xiong Haiqing from the Chinese Academy of Medical Sciences Blood Disease Hospital, with contributions from several co-authors and support from various national and local funding programs [3]

Group 1 - The core viewpoint of the article is that the Chinese CRO industry is transitioning from being mere service providers to becoming innovative ecosystem builders, as highlighted by Dr. Duan Maosheng at the ACCESS ASIA forum [1] - The forum discussed cutting-edge topics such as antibody-drug conjugates (ADC), cell and gene therapy (CGT), and AI-driven drug discovery, reflecting global capital's interest in innovation [1] - China is increasingly important in the global pharmaceutical innovation landscape due to its regulatory alignment with international standards, talent return, and technological accumulation [1] Group 2 - Mediso, a leading one-stop drug R&D service platform, has invested approximately 2,000 square meters in a research office in Boston to support its globalization strategy and meet the growing demands of overseas clients [2] - The company emphasizes its role as a partner alongside clients, not just a service provider, and aims to help clients navigate asset valuation, development planning, and international negotiations [2] - Mediso has supported the successful internationalization of multiple innovative drugs and is focused on aiding emerging pharmaceutical companies in their global strategies [3] Group 3 - As of now, Mediso has participated in the development of 588 new drug projects that have received clinical trial approvals from regulatory bodies such as China's NMPA, the US FDA, and Australia's TGA from 2015 to June 2025 [3] - The company has averaged about 100 IND approvals annually in the past three years, accelerating the drug development process [3] Group 4 - Huaxi Securities has raised its earnings forecast for Mediso, anticipating that the company will benefit from improving domestic market conditions and has maintained a "buy" rating [5]